Intervention

Leucovorin

ClinicalTrials.gov intervention label

Clinical trials29

Recruiting4

Common conditions25

Lead sponsors shown15

Clinical trials

29 shown

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)NCT03109288 · 2017-08-11

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.NCT06704724 · 2024-12-10

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185 · 2024-10-21

ACTIVE_NOT_RECRUITING

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662 · 2024-06-27

ACTIVE_NOT_RECRUITING

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738 · 2024-05-30

ACTIVE_NOT_RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171 · 2023-10-13

ACTIVE_NOT_RECRUITING

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNCT05714553 · 2023-03-08

First in Human Study of AZD9592 in Solid TumorsNCT05647122 · 2022-12-21

ACTIVE_NOT_RECRUITING

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)NCT05239741 · 2022-04-02

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionNCT04882241 · 2020-07-29

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNCT03554109 · 2018-09-01

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.NCT03387085 · 2018-03-19

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)NCT03374254 · 2018-02-16

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyNCT03175666 · 2017-12-01

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)NCT03221426 · 2017-10-09

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinNCT03131973 · 2017-05-13

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)NCT03085914 · 2017-05-02

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerNCT02735239 · 2016-06-24

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerNCT02124148 · 2014-06-18

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsNCT01803282 · 2013-03-29

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast CancerNCT01231802 · 2011-04-01

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)NCT01183663 · 2010-08-01

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of ResponseNCT01258634 · 2010-07-01

Chemotherapy and HAART to Treat AIDS-related Primary Brain LymphomaNCT00267865 · 2006-09-14

Common conditions

Leading sponsors

Merck Sharp & Dohme LLC6 ImmunityBio, Inc.3 Pfizer3 Eli Lilly and Company2 National Cancer Institute (NCI)2 Adherex Technologies, Inc.1 Arcus Biosciences, Inc.1 AstraZeneca1 Bristol-Myers Squibb1 Enliven Therapeutics1 Gilead Sciences1 Incyte Corporation1 Ludwig Institute for Cancer Research1 M.D. Anderson Cancer Center1 National Institute of Allergy and Infectious Diseases (NIAID)1

Trial status mix

COMPLETED10

ACTIVE_NOT_RECRUITING6

TERMINATED6

RECRUITING4

WITHDRAWN2

UNKNOWN1

Phase mix

PHASE121

PHASE211

PHASE34

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.